PFS Partners’s Takeda Pharmaceutical TAK Stock Holding History

PFS Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.18K	Hold	136	–	–	﹤0.01%	532
2026 Q1	$2.52K	Sell	136 -91	-40%	-$1.6K	﹤0.01%	502
2025 Q4	$3.54K	Hold	227	–	–	﹤0.01%	465
2025 Q3	$3.32K	Hold	227	–	–	﹤0.01%	463
2025 Q2	$3.51K	Hold	227	–	–	﹤0.01%	425
2025 Q1	$3.38K	Hold	227	–	–	﹤0.01%	368
2024 Q4	$3.01K	Hold	227	–	–	﹤0.01%	380
2024 Q3	$3.23K	Hold	227	–	–	﹤0.01%	379
2024 Q2	$2.94K	Hold	227	–	–	﹤0.01%	369
2024 Q1	$3.15K	Hold	227	–	–	﹤0.01%	390
2023 Q4	$3.24K	Hold	227	–	–	﹤0.01%	381
2023 Q3	$3.51K	Hold	227	–	–	﹤0.01%	368
2023 Q2	$3.57K	Hold	227	–	–	﹤0.01%	386
2023 Q1	$3.74K	Hold	227	–	–	﹤0.01%	297
2022 Q4	$3.54K	Hold	227	–	–	﹤0.01%	286
2022 Q3	$2.94K	Hold	227	–	–	﹤0.01%	283
2022 Q2	$3.19K	Hold	227	–	–	﹤0.01%	274
2022 Q1	$3.25K	Hold	227	–	–	﹤0.01%	286
2021 Q4	$3.1K	Buy	+227	New	+$3.18K	﹤0.01%	288

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

PFS Partners's TAK Position: Q2 2026 in Review

PFS Partners held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 136 shares worth $2.18K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

PFS Partners first reported a position in TAK in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.74K in Q1 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

PFS Partners held 136 shares of Takeda Pharmaceutical worth $2.18K as of Q2 2026.
PFS Partners left its Takeda Pharmaceutical share count unchanged in Q2 2026.
Takeda Pharmaceutical made up ﹤0.01% of PFS Partners's portfolio in Q2 2026, its #532 holding.
PFS Partners first reported a position in Takeda Pharmaceutical in Q4 2021 and has held it in 19 quarters since.
PFS Partners's Takeda Pharmaceutical position peaked at $3.74K in Q1 2023.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on PFS Partners's 13F filing for Q2 2026, filed 20 Jul 2026.